MedTrace Logo

Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

NCT05391022 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-07-28

No results posted yet for this study

Summary

Phase 1 2-part study to evaluate the effect of food on pharmacokinetics of pelabresib (CPI-0610) and the effect of pelabresib on QTc in patients with advanced malignancies

Conditions

  • Advanced Malignancies
  • Solid Tumor
  • Hematological Malignancy

Interventions

DRUG

Pelabresib

Pelabresib monohydrate tablets

Sponsors & Collaborators

  • Constellation Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-20
Primary Completion
2023-03-08
Completion
2024-02-29
FDA Drug
Yes

Countries

  • United States
  • Georgia
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05391022 on ClinicalTrials.gov